Exclusive Summary

• Dual-Targeting Mechanism Addressing Resistance: UB127 features an EGFR x c-Met bispecific design, engineered to overcome tumor heterogeneity and compensatory c-Met signaling often seen after EGFR-TKI resistance.
• Proprietary Platform Enhancing Safety: Utilizes the ExSAC™ Linker-Payload technology (novel TOP1i), offering a wider therapeutic window and superior safety profile compared to conventional DXD-based ADCs in preclinical models.
• Superior Preclinical Efficacy: Demonstrates superior tumor growth inhibition in low-expression and heterogeneous models compared to single-target EGFR-ADCs, showing Best-in-Class potential.
• Clean Global Rights: Currently in the IND-enabling stage with fully available global rights (Ex-China/Global), offering flexible partnership models (Licensing-out or NewCo) regarding Lung Cancer pipelines.

Asset Materials

Contact Us for Full Materials